Search PubMed⌕ Search

Biomedical subjects

G Y Terashita

Publications and source records attributed to G Y Terashita.

7 recordsLinked to original sources
PubMed1989

Platelet crossmatching for kidney transplants by flow cytometry.

Although flow cytometry crossmatching is now performed by many kidney transplant centers, it yields a high false-positive rate, as evidenced in the present series by a 71% one-month success rate despite a positive crossmatch. In an attempt to reduce false-positive reactions while retaining the sensitivity of the flow cytometer, platelets were tested as targets. Whereas flow cytometry with T cells was not correlated with one-month failure rates, retrospective platelet crossmatching by flow cytometry showed that kidney failure within one month occurred in 53% of 19 patients with a positive platelet crossmatch compared with 15% of 48 patients with a negative platelet crossmatch. (P less than 0.002). Statistical significance in one-month outcome was also obtained when only first transplant patients were analyzed (P less than 0.04). The present results suggest that crossmatching with platelet targets may be a simpler way to avoid early primary nonfunction while minimizing false-positive reactions.

Blood Grouping and Crossmatching↗
PubMed1989

Flow cytometry crossmatching: an update.

1. Data obtained since the implementation of the T-cell flow cytometry crossmatch (T-FCXM) on a prospective basis verify the effectiveness of the T-FCXM for sensitized patient groups. Relative ineffectiveness of the T-FCXM when applied to nonsensitized patient groups is due to substantially reduced sensitivity for these patient groups. 2. Overall, a T-FCXM reaction of greater than 10 channels is associated with increased incidence of kidney nonfunction at 1-month posttransplant. Higher antibody levels, indicated by T-FCXM reactions of greater than 20 channels, are associated with increased incidence of kidney function delayed beyond the first week posttransplant. 3. The platelet FCXM (PL-FCXM) is somewhat more specific, but also somewhat less sensitive than the T-FCXM. Generally speaking, raising the threshold for defining a positive T-FCXM from the standard 10 channels to 20 channels results in performance similar to that of the PL-FCXM, when the tests are used individually. 4. The PL-FCXM used in conjunction with the standard T-FCXM can substantially reduce the false-positive rate of the T-FCXM, thus increasing the usefulness of the FCXM significantly. 5. We hope that the T-FCXM has contributed to continued improvement in renal transplant outcome over the past few years. However, from the number of cases of sensitized patients being transplanted across a positive FCXM, it appears that many more cases of nonfunctioning transplanted kidneys could be avoided by fully implementing the T-FCXM for sensitized patients.(ABSTRACT TRUNCATED AT 250 WORDS)

Blood Platelets↗
PubMed1988

Crossmatching on platelets by flow cytometry.

1. HLA antigens on platelets can be detected by alloantisera used for typing lymphocytes. 2. There is a general correlation between reactivity of sera against platelets and reactivity against T cells. However, some SLE patients have broadly reactive antibodies to T cells that are much less reactive to platelets. These sera may contain IgG autoantibody to non-HLA T-cell autoantigens. 3. The Pl-FCXM may be both more sensitive than the conventional cytotoxic crossmatching techniques and more discriminating than the T-FCXM in detecting relevant deleterious antibodies. All 11 patients with a negative platelet FXCM had functioning kidneys at 1 month, whereas 7 of 12 patients with a positive Pl-FCXM had nonfunctional kidneys at 1 month (p = 0.003). 4. It is suggested that the Pl-FCXM offers a simple, sensitive, and effective method of crossmatching without the high false positive rate of T-FCXM.

Blood Platelets↗
PubMed1987

Original disease of the recipient.

1. The use of CsA in cadaver donor transplants has apparently overcome the effect of original disease one-year graft survival rates. Only SLE patients had lower than average graft survival rates in CsA-treated, first transplants. 2. Since 1970, the proportion of diabetics transplanted has increased tenfold. The proportions of transplants for glomerulonephritis and pyelonephritis have decreased over the years. 3. A beneficial effect of pretransplant blood transfusions, was observed in almost all of the disease groups. 4. HLA matching, particularly for HLA-B, DR antigens, has resulted in increased graft survival rates in the major disease categories. Small numbers of zero mismatched grafts prevented a more detailed analysis. 5. Whereas CsA consistently enhanced graft survival rates for first cadaver transplants, this drug had a much smaller effect in living donor transplants. A 14% increase was seen in cadaver donor transplants due to CsA, compared to 2% (siblings), 1% (parent), and 4% (child) for the living donor grafts.

Adolescent↗
PubMed1985

Detection of tumor-associated antigens in the sera of lung cancer patients by three monoclonal antibodies.

One hundred sixty-one sera from lung cancer patients, including 46 samples from patients who had not yet received treatment were screened for tumor-associated antigens with 3 monoclonal antibodies, CSLEX1, CSLEA1, and CLEX5, by a new cell binding inhibition assay. We had previously determined that the antigens recognized by CSLEX1 and CSLEA1 are sialosylated Lewisx and sialosylated Lewisa, respectively. Either of these two antibodies alone reacted with about 65% of the 46 untreated patients' sera. Eighty-seven % of the 46 showed positive results with at least one of the two antibodies. The CLEX5 monoclonal antibody is presented here as recognizing a potential tumor-associated antigen. CLEX5 reacted with 54% of the 46 sera from nontreated lung cancer patients. When the results for all three antibodies were combined, the percentage of positive sera was 89% (of 46). Some interesting patterns in the serum levels of the antigens detected by these antibodies were observed. Levels of sialosylated Lewisx were significantly higher in sera from nontreated advanced stage (III and IV) patients (P less than 0.0003). In addition, levels of the antigens detected by CSLEX1 and CSLEA1 were dependent on whether or not the patient had been receiving treatment. These observations suggest potential applications of monoclonal antibodies to diagnosis and monitoring of therapies.

Adenocarcinoma↗
PubMed1985

Sialosylated Lewisx in the sera of cancer patients detected by a cell-binding inhibition assay.

A new cell-binding inhibition assay to detect tumor-associated antigens in sera was developed. This assay determined that sialosylated Lewisx, as detected by the CSLEX1 monoclonal antibody, is present in the sera of 95% of patients with advanced lung adenocarcinomas. Sera with inhibition titers of 1:16 or higher were presumed to contain sialosylated Lewisx. Tests of over 900 sera samples from both malignant and benign disease patients yielded the following percentages of positive inhibition: lung cancers, 43.8%; stomach cancer, 26.0%; colon cancer, 44.4%; gall bladder and bile duct cancers, 47.8%; pancreas cancer, 37.5%; breast cancer, 26.7%; cancers of the hematopoietic system, 2.9%; benign diseases, 0.9% (332 sera); and normal healthy donors, 0.7% (280 sera). Within the lung cancer group, 95% of the sera from 21 advanced (Stages III and IV) nontreated adenocarcinoma patients gave positive results with high inhibition titers, whereas only 27% of sera from treated advanced adenocarcinoma patients yielded positive results. The sensitivity of the cell-binding inhibition assay is similar to those of the solid-phase radioimmunosandwich and reverse passive-hemagglutination assays. Reproducibility tests yielded an r value of 0.90. These results suggest that this simple cell-binding inhibition assay could be applied with monoclonal antibodies, such as CSLEX1, to monitor cancer.

Antibodies, Monoclonal↗